Your shopping cart is currently empty

1G244 is an inhibitor of DPP8/9 with antiatherosclerotic and antimyeloma properties. 1G244 had the IC50 values of 14 and 53 nM against DPP8 and DPP9, and The Ki values for 1G244 were 0.9 and 4.2 nM for DPP8 and DPP9

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $33 | In Stock | In Stock | |
| 10 mg | $53 | In Stock | In Stock | |
| 25 mg | $106 | In Stock | In Stock | |
| 50 mg | $173 | In Stock | In Stock | |
| 100 mg | $283 | - | In Stock | |
| 500 mg | Preferential | - | In Stock |
| Description | 1G244 is an inhibitor of DPP8/9 with antiatherosclerotic and antimyeloma properties. 1G244 had the IC50 values of 14 and 53 nM against DPP8 and DPP9, and The Ki values for 1G244 were 0.9 and 4.2 nM for DPP8 and DPP9 |
| Targets&IC50 | DPP9:4.2 nM(ki), DPP8:14 nM, DPP8:0.9 nM(ki), DPP9:53 nM |
| In vitro | 1G244 (0-100 μM) dose-dependently decreased viable cell number of five multiple myeloma cell lines as well as three T-cell lymphoma cell lines[2]. |
| In vivo | The apoE−/− mice treated with 1G244 (1G244 dissolved in 75% PEG 300, 2 mg/kg) showed that 1G244 reduced the area of advanced atherosclerotic lesions by about 14%[1]. 1G244 was administered subcutaneously into mice at 30 mg/kg once a week, administration of 1G244 apparently suppressed the subcutaneous growth of MM.1 S cells[2]. |
| Molecular Weight | 504.57 |
| Formula | C29H30F2N4O2 |
| Cas No. | 847928-32-9 |
| Smiles | N[C@@H](CC(=O)N1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1)C(=O)N1Cc2ccccc2C1 |
| Relative Density. | 1.304 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (495.47 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.91 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.